• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

AbbVie Gets a Shot in the Arm With Allergan Buy, but Now Look Elsewhere

The deal makes sense for growth - and for Allergan shareholders - but now the price and uncertainty make this stock hard to swallow.
By STEPHEN GUILFOYLE
Jun 25, 2019 | 12:23 PM EDT
Stocks quotes in this article: ABBV, AGN, IBM, RHT, CRM, DATA, PFE, ARRY, INCY

Approximately $63 billion. So, it is that price at which AbbVie ( ABBV)  has agreed to buy Allergan ( AGN) . It's not a problem at all when a firm -- who finds its own growth slowing -- goes out and buys growth. Often the acquirer ends up paying what looks like more than a bundle for this renewed opportunity to grow. IBM  ( IBM) comes quickly to mind, with the Red Hat ( RHT) deal. We have seen this in tech over and over, and not just to grow. Salesforce.com  ( CRM) was indeed having no issue increasing sales at their steady pace, when it reached to grab first Mulesoft, and now, Tableau Software  ( DATA)  to more perfectly refine an already best-in-breed business of cloud offerings. Is this refining what AbbVie was after, or more of a grab for growth? Let's explore. 

Taking a Look

At first glance, both firms seem to be having a rough go of it. That said, I think Allergan CEO Brenton Saunders deserves a big round of applause. AGN shareholders will receive for each share, $120.30 in cash (the shares closed on Monday night at $129.57), as well as 0.866 share of ABBV in exchange. Wow, nice trade.
 
Shares of AGN have struggled for year now, trending regularly lower, with the exception of a nice respite mid-2018 that eventually petered out. In May, however, AGN surprised Wall Street with solid fiscal second-quarter beats for both earnings per share and revenue, though revenue still showed year-over-year contraction. There were two interesting takeaways from that release. One, the firm raised full-year guidance for both sales and adjusted profitability. Two, Botox -- plain and simple. Botox is Allergan's best-selling product at more than $868 million for the quarter, good for 6.3% growth. It easily out-performs most of the rest of the firm's portfolio of products.
 
Hence, AbbVie needs to diversify its own portfolio, even if forced to pay up for growth, as Humira, its best-selling auto-immune treatment will lose patent protection and face stiff, cheaper competition by 2023. By the way, Humira is worth about 60% of AbbVie's aggregate revenue generation. This move came of nothing but necessity, despite some overlap across other product lines such as treatments brain disorders and women's health. 

My Thoughts

For shareholders of Allergan, congratulations. That ship has now sailed. Take a victory lap and move on to the next thing. AbbVie becomes interesting now, but at what price does it make sense? I don't think that I take a shot at either of these stocks. I think that in the wake of this deal -- and the Pfizer ( PFE)  purchase of Array BioPharma ( ARRY)  -- that playing other names would be of interest. Look for names in the space that on their own merits also have the ability to attract the attention of Big Pharma. Remember, we fast approach another election season, and just about the only thing that Democrats and Republicans agree on is using Big Parma as a political pinata.
 
One name I have been watching as I look for a technical breakout is Incyte ( INCY) , a U.S.- company, whose lead product treats blood cancer. In fact, I'm long (small) on INCY.
 
 
Look how volatile the chart is? Yet, the shares based for most of 2018 after a significant beat-down, then used prior resistance as support as the shares consolidated on top of that base. Now... it's poised to break out again. Worthy of some risk? Yes, in my opinion. Not only are earnings and sales both growing like a weed for this name, but from December through March, the firm saw a 13.6% increase in the number of funds that had taken a stake, all while management has retained 17% ownership of the company. The downside? The shares trade at 30-times forward-looking earnings.
 
Salesforce.com (CRM) is a holding in Jim Cramer's Action Alerts PLUS member club.
 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was long (small) on INCY.

TAGS: Mergers and Acquisitions | Investing | Stocks | Pharmaceuticals | Stock of the Day

More from Stocks

Bearish Bets: 2 Nasdaq Stocks You Should Consider Shorting This Week

Bob Lang
Feb 28, 2021 10:30 AM EST

These names are displaying both quantitative and technical deterioration.

Jim Cramer: What History Tells Us About Bond-Rate Scares Like This

Jim Cramer
Feb 27, 2021 2:01 PM EST

We could have some real pain ahead for some stocks. Five different kinds.

Navigating a Market Correction

James "Rev Shark" DePorre
Feb 27, 2021 10:00 AM EST

The most critical factor in long-term market success is the ability to effectively navigate market corrections.

Corrective Action Produces Fading Confidence and Technical Damage

James "Rev Shark" DePorre
Feb 26, 2021 5:08 PM EST

It's dangerous to have too much exposure now, but the potential for a good recovery is there once interest rate issues are digested.

I'm Intrigued by the Recent Pullback in Aurora Mobile

Timothy Collins
Feb 26, 2021 3:30 PM EST

While the Chinese company is still not profitable, it is cash flow positive.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:51 AM EST REAL MONEY

    Watch Bob Lang and Doug Kass Discuss Short-Selling!

    Bob Lang and Doug Kass with an engaging and educat...
  • 11:32 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Navigating a Market Correction
  • 11:29 AM EST GARY BERMAN

    Where Does the Nasdaq Go From Here?

    Where does the Nasdaq Composite (CCMP) index go fr...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login